Modus Create Acquires Romanian Software Engineering Firm Clarisoft
10.1.2023 16:03:00 EET | Business Wire | Press release
Modus Create, a digital transformation consulting firm, announced today that it has acquired Clarisoft, a Romanian software engineering company with deep expertise in custom product development for enterprises.
This is Modus Create’s fifth acquisition in the last 12 months, topping off a year of accelerated growth and inclusion on the Inc. 5000 list for the eighth successive time. Since May, Modus Create has expanded its offerings through the acquisitions of software engineering company Tweag; product development firm Promptworks; and Atlassian consulting firms Atlas Authority and Twybee. The acquisition of Clarisoft represents Modus Create’s third acquisition in the European market.
Headquartered in Bucharest, Romania, Clarisoft is known for building quality software across enterprise, mid-market, and government clients worldwide, particularly in sectors such as healthcare, automotive, finance, and telecom. Its clients include organizations such as Cisco and Livongo Health.
Clarisoft’s CEO Bogdan Bucura will join Modus in a sales leadership role, and Development Director Mircea Enache will take on a delivery leadership role. Also joining Modus will be 40 senior engineers, designers, and project managers.
“We continue to add capabilities and talent that deepen Modus Create’s expertise as a leading global partner for product development. Adding Clarisoft to the team expands our European footprint and strengthens our offerings in enterprise software development, leading cloud platforms, and microservices delivery,” said Sarah McCasland, Chief Strategy Officer, Modus Create. “Most importantly, Clarisoft is a cultural fit that will seamlessly integrate with the Modus values of creating high-quality products for our clients.”
“By joining Modus Create, I saw an opportunity for Clarisoft to be a part of a bigger organization while still providing the type of service our clients expect,” said Bogdan Bucura, CEO, Clarisoft. “We will bring expertise in areas such as Microsoft Azure, broadening the scope of Modus’ already highly respected software engineering team. And we look forward to offering our clients the broader services Modus has in areas such as platform modernization and digital operations.”
About Modus Create
Modus Create is a digital consulting firm dedicated to helping clients build competitive advantage through digital innovation. We support organizations across their transformation journey with strategic consulting and full lifecycle product development. Our global team of strategists, designers, and technologists has created powerful digital experiences for some of the world’s biggest brands. Visit moduscreate.com to learn more.
About Clarisoft
Clarisoft Technologies is a top software development company with offices in Europe and the USA. We offer full-stack digital solutions for business and staff augmentation through outsourcing services in Romania. We provide high-quality and cost-effective custom software development and mobile application development services for enterprises.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005166/en/
Contact information
Ellie Behling
Modus Create
ellie.behling@moduscreate.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom